Trial Profile

A phase 2b, randomised, double-blind, vehicle-controlled study analyzing AB-101a in patients with AD

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB 101 Alphyn Biologics (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Sponsors Alphyn Biologics

Most Recent Events

19 Feb 2025 According to an Alphyn Biologics media release, the company anticipates the initiation of the global Phase 2b trials of Zabalafin Hydrogel in the first quarter of 2025.
21 Aug 2024 According to an Alphyn Biologics media release, company anticipates Phase 2b trials will begin in the U.S., Europe, and Australia in 2025.
07 Mar 2024 According to an Alphyn Biologics media release the initiation of this study is expected in second half of 2024, as the company is raising series B funding.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com